News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

European Patent Office Grants Patent For Oral Administration Of GlycoGenesys, Inc. (Formerly SafeScience, Inc.) (GLGS) Cancer Drug Candidate


10/19/2005 5:09:56 PM

Patent Protects Oral Use of GCS-100(R) and Other Modified Pectin Compounds in Multiple Cancers GlycoGenesys, Inc., (Nasdaq: GLGS), a biotechnology company developing carbohydrate-based drugs, today announced that the European Patent Office has issued a patent protecting the oral use of the Company's lead drug candidate GCS-100 for the treatment of cancer in Europe. The Company exclusively licenses this patent from Wayne State University and the Barbara Ann Karmanos Cancer Institute.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES